Aleix Prat: Unlocking the potential of engineered immune cell therapy for solid tumors
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared an article on LinkedIn he and his colleagues authored:
“New publication alert!
Excited to share our latest work published in Nature Communications: “Unlocking the potential of engineered immune cell therapy for solid tumors”
Adoptive cell therapy (ACT) has revolutionized the treatment landscape of hematologic malignancies, but solid tumors remain a formidable challenge. In this piece, we explore how genetic engineering strategies—ranging from immune checkpoint silencing to metabolic reprogramming—are paving the way for more effective and durable immune cell therapies in solid tumors.
Key takeaways:
– Advances in TIL, CAR-T, and TCR-T therapies are expanding treatment options.
– Genetic editing techniques (e.g., CRISPR) can enhance T-cell persistence and function.
– Armored T cells and metabolic reprogramming hold promise for overcoming the tumor microenvironment.
– Beyond T cells, the future lies in engineered macrophage and NK cell therapies, as well as allogeneic ‘off-the-shelf’ solutions.
A huge thank you to Víctor Albarrán Fernández, who led this Comment, Laura Angelats, Julio Delgado, Alena Gros Vidal, Álvaro Urbano-Ispizua, and Sonia Guedan.”
Unlocking the potential of engineered immune cell therapy for solid tumors
Authors: Víctor Albarrán-Fernández et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023